Date: Monday, August 17, 2026

Overview

Join NACHC for its 340B Day at our CHI - Community Health Conference on Monday, August 17. This immersive day of education sessions will provide health centers with the tools to enhance compliance with the 340B program, best practices to protect and increase pharmacy reimbursement for all pharmacy arrangements, and advocacy strategies to protect 340B savings at the federal and state level. 

Who Should Attend

No need to fear- you do not need to be a 340B expert to participate in 340B Day! While we will dive into the weeds on some topics, the sessions are designed for anyone in the health center to learn from.  

Agenda

8:15 – 9:15 AM
340B Federal and State Update 

For nearly three decades, the 340B Drug Pricing Program has been a vital resource for health centers (HCs), enabling access to prescription drugs and allowing savings to be reinvested into patient care. Today, the program faces heightened scrutiny and significant challenges, alongside evolving federal and state policy activity.

Join NACHC and leading 340B experts for an in-depth update on the latest federal and state policy developments affecting the 340B program. This session will examine emerging trends, legal and regulatory actions, and their practical implications for HCs, while offering strategies to help covered entities navigate uncertainty and protect program sustainability.

Speakers: 

• Elizabeth Linderbaum, MPP, Director, Regulatory Affairs, NACHC

---

1:00 - 2:00 PM
What's Next? The Realities of a 340B Rebate Model 

After Health Resources and Services Administration’s 2025 attempt to implement a 340B rebate model was halted by federal courts due to likely administrative law violations, efforts to implement a rebate model have not stopped. HRSA restarted the process to implement a rebate model in February 2026 with an Information Collection Request to the field on the burdens and opportunities of a rebate model, signaling the fundamental restructuring of the 340B program is far from over.

A rebate model would shift 340B from upfront discounts to a post-purchase reimbursement structure, creating significant implications for cash flow, compliance infrastructure, and administrative burden for community health centers (CHCs). These changes could disrupt pharmacy operations, alter financial forecasting, and increase operational complexity at a time when many community health centers are already navigating contract pharmacy restrictions and evolving manufacturer policies.

NACHC has led a coordinated advocacy campaign to uplift the negative impact of a rebate program on CHCs through regulatory, legislative, and grassroots actions. This session will provide the latest policy and legal updates, clarify what is known and unknown about the proposed rebate framework, and outline realistic implementation scenarios.

Speakers will examine how a rebate model may function operationally, assess the financial and compliance risks for CHCs, and share practical advocacy strategies participants can implement immediately. Attendees will leave better equipped to evaluate organizational risk, engage policymakers effectively, and prepare their health centers for multiple potential 340B futures.

Speakers: 

• Elizabeth Linderbaum, MPP, Director, Regulatory Affairs, NACHC

---

2:45 - 3:45 PM
Infusion Centers and 340B: a Case Study for Improved Access and Compliance

In the face of ever-diminishing reimbursement and financial support despite ever-increasing needs for access to essential care, many health centers have considered the potential for partnering with or operating an infusion center, which appears to hold the promise of improving comprehensive patient care options while also returning vital 340B prescription drug savings. However, health centers evaluating such options must consider many factors across the broader 340B ecosystem, including contract pharmacies, pharmacy management services companies (MSOs), third-party administrators (TPAs), and pharmacy benefit managers (PBMs), among others.

The session will achieve three learning objectives: (1) it will provide an overview of the 340B considerations associated with infusion center partnerships and operations, including common risk areas, pharmacy management fees, patient assistance and discounting programs, prescription retention strategies, and vendor-driven referral dynamics; (2) it will examine how compensation methodologies, data-sharing arrangements, patient encounters, and performance incentives may affect compliance; and (3) it will provide recommendations and considerations from a health center’s perspective for several infusion center models.

Participants will leave with practical tools to strengthen governance, contracting, and mitigate enforcement risk to structure compliant partnerships and operations for this potential enhancement to a health center’s patient service and 340B savings.

Speakers: 

• Gabriel Garcia, Esq., Partner, Feldesman LLP
• Steve Kuperberg, Esq., Partner, Feldesman LLP
• Megan Rusby, PharmD, Associate Director of Pharmacy/Residency Program Director, Penobscot Community Health Care

---

4:30 - 5:30 PM

What's So Special? A Deep Dive into Specialty Pharmacy Accreditation

According to the Centers for Disease Control and Prevention (CDC), four in ten Americans have more than one chronic condition. Many of these conditions, like Rheumatoid arthritis and Hepatitis C, require specialty medications with strict handling, storage, and administration requirements. Pharmacy Benefit Managers (PBMs) and health plans often mandate that pharmacies dispensing a high volume of specialty medications obtain a ‘specialty pharmacy accreditation’ to do so. While KFF estimates that over 74,000 pharmacies existed in 2024 (many of which were at or contracted with community health centers), only about 1,900 pharmacies have received a specialty pharmacy accreditation, according to the Drug Channels Institute. Specialty pharmacy accreditation can also unlock new revenue streams, as roughly 40 percent of the national drug spend is on specialty drugs.

With multiple accreditation bodies and a changing landscape of contract and entity-owned pharmacies, community health centers may feel overwhelmed about where to begin their specialty pharmacy journey. This session will share best practices and strategies for health centers and other stakeholders to consider when pursuing specialty pharmacy accreditation. Speakers from various health centers that have achieved accreditation will discuss the process, from assessing feasibility to reaccreditation. They will also explore how partnerships with other specialty pharmacies can be beneficial if the patient population using specialty medications is not large.

Speakers: 

• Elizabeth Linderbaum, MPP, Director, Regulatory Affairs, NACHC

Key Details

Contact Elizabeth Linderbaum, Deputy Director of Regulatory Affairs for more information. 

Pricing 

This year, the event is free for fully registered conference attendees or those registering for the Tuesday-only option!